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Abstract
Virus Clearance is one of the major challenges in biopharmaceutical industry, especially
in the manufacturing of drugs. U.S. Food and Drug Administration (FDA) recommends using
several model bacteriophages as surrogates of pathogenic mammalian virus for process
validation. In this work, two bacteriophages were tested against 30 kDa, 100 kDa, 300 kDa
polyethersulfone (PES) membranes to investigate the effects of pore size on virus clearance.
Virus particles were spiked into the protein feed solutions containing bovine serum albumin
(BSA) or lysozyme at different concentrations. Besides protein concentration, the effects of feed
pH on the filtration performance and virus rejection were also investigated.
The results indicate that 100 kDa PES membrane can remove 4 logs of virus from the
feed stream with and without protein while maintaining a moderate flux performance. pH does
not appear to significantly affect the virus rejection. However, flux is somewhat higher when the
pH of the feed is close to neutral. These results indicate that electrostatic interaction between the
protein, virus particle and the membrane has a strong effect on flux and virus rejection.

Acknowledgments
I would like to extend my gratitude to my graduate advisor Prof. Xianghong Qian as well
as Prof. Ranil Wickramasinghe for the support and guidance on the project. I would also like to
thank Dr. Satchithanandam Eswaranandam and all the other group members for helping me set
up the filtration experiments.

2

Table of Contents
1.

Introduction………………………………………………………………….…....……...1

1.1.

Bioprocess Overview …………………………………………………………...………..1

1.2.

Virus Clearance ………………………………………………………………..………...2

1.3.

Virus Filtration ………………………………………………………………..…………5

1.3.1. Virus Filtration Membranes…………..……………………………………...……….…5
1.3.2. Virus………..……………………………………………………………………....…...…7
2.

Material and Methods………………………………………………………….…...…....8

2.1.

Materials ……...…………………………………………………...…………….…...…...8

2.2.

Virus Stock Preparation …………...………………………………………...….……….9

2.3.

Flux Measurement ……………...………………………………………...….…….……..9

2.4.

Titer Analysis ……………………………………………………….….…….….………10

3.

Results and Analysis …………………………………………………………….………11

3.1.

Pore Size Effect …………………………………………………………………….…....11

3.2.

Protein Spiking Effect ……………………………………………..…………………....14

3.3.

pH Effect ……………………………………………………………………...….……....21

3.4.

Phage spiking Effect …………………………………………………...………….…….24

4.

Discussion ………………………………………………………………...……….….….26

5.

Future Directions ……………………………………………………………...…..…….27

6.

References …………………………………………………………………...…..……….28

3

1.

Introduction

1.1.

Bioprocess Overview

Since the first therapeutic murine monoclonal antibody (mAb) was introduced into clinical
studies in 1980s, major pharmaceutical companies started to invest on developing therapeutic
mAbs and mAb fragments because of their higher Likelihood of Approval (LOA) over small
molecule therapeutics and the diversification they bring to the therapeutic pipeline (Reichert et al.
2005). By end of 2016, a total of 67 mAbs have been approved by FDA and this number is
continuously growing with approximately four new mAbs per year (Ecker et al. 2015). The
global market of mAbs production has reached 74.5 billion USD and is projected to grow at a
compound annual growth rate (CAGR) of 12.2% during the next four years (BCC Research,
2013).
The manufacturing of monoclonal antibodies can be divided into two processes (Shuler et
al. 2002): 1) an upstream bioprocess using genetically modified cell lines to produce raw
materials from the upstream bioreactors; 2) a downstream bioprocess using a validated mAb
purification platform that consists of different purification steps to meet the regulatory
requirements. Depends on the actual purification platform, the number and types of purification
steps may vary (Sommerfeld, et al., 2005).
The main goal of downstream bioprocessing is to remove impurities and any potential
contaminants i.e. nucleic acids, host cell proteins(HCP), product variants, endotoxins, viruses
and other small molecule impurities to a certain level (Serabian et al., 1999). For example, the
acceptable range of host cell protein in the mAb products is 1-100 ng/mg (nanogram HCP per
gram mAb) (Wang et al., 2015).
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1.2.

Virus Clearance

Viral contamination can be introduced by endogenous viruses that comes from the specific cell
lines being used for mAb production, and/or by adventitious viruses that comes from
contaminated reagents, buffers or unappropriated product handling during the manufacturing
process (Brorson et al., 2004). Considering the potential risk of viral contamination during mAb
manufacturing process, virus clearance has become one of the key performance indicators (KPI)
of the quality assurance steps (Wu et al., 2008).
Food and Drug Administration (FDA) Center for Biologics Evaluation and Research
(CBER) provides several process validation regulatory guidelines for viral clearance during
biopharmaceutical manufacturing. In the document entitled Points to Consider in the
Manufacture and Testing of Monoclonal Antibody Products for Human Use (1996), CBER
recommended that each purification protocol for mAb production must include at least two
orthogonal (based on different mechanisms) robust virus removal steps. Robust virus removal/
inactivation steps are defined as the ones that have been proven to perform well under various
operation conditions, such as different pH and ionic strength across different mAbs. According
to the aforementioned FDA guidelines, inactivation of virus with low pH, heat inactivation and
virus filtration are all considered to be robust steps. CBER also emphasizes the importance of
virus clearance studies and implies using several model viruses of different types: large and
small viruses, DNA and RNA viruses, chemically sensitive non-enveloped viruses and resistant
lipid enveloped viruses. In another document entitled Viral safety evaluation of biotechnology
products derived from cell lines of human or animal origin Q5A (1999), ICH (International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use) elaborates three principles and complementary approaches to control potential viral
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contaminations during manufacturing process including 1) encompass selecting/testing of the
cell lines and raw materials, 2) quality inspection on end products for absence of infectious
viruses 3) validating virus clearance steps in the manufacturing process.
There have been tremendous efforts dedicated to developing robust methods that can
inactivate and remove viruses from pharmaceutical products during the downstream
bioprocessing. To evaluate different methods for virus clearance, log removal value (LRV) is
used. It is considered effective if LRV of a method is above four, moderately effective if the
LRV is between 1-4 and ineffective if LRV is less than one (Smith, 2014). Generally, virus
inactivation by breaking down the viral genetic materials using gamma radiation and ultraviolet
radiation that can result in a LRV of 2 to 6. Virus inactivation by dissolving lipid envelope of
enveloped viruses using solvent/detergent can achieve a LRV of more than 6 (Shukla et al. 2006).
In addition to the abovementioned virus clearance methods, many other processes in capturing
and purification sections, such as protein A chromatography, ion exchange chromatography,
membrane chromatography and flocculation et al. can also remove viruses even though they are
not generally considered as dedicated virus clearance steps (Curtis et al. 2003, Parkkinen et al.
2006).
Virus inactivation can cause damages to the virus particles and render the virus particles
inactive. However, the majority of virus particles remain in the final product instead of being
removed from the process stream. In order to physically remove both intact virus particles and
damaged virus particles, more robust virus clearance steps will need to be incorporated into the
mAb manufacturing platform in addition to the virus inactivation steps. Virus filtration is among
the most robust methods that is based on size exclusion of porous membranes and can
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consistently result in a LRV of 3-6 with very low batch to batch variations (Kuriyel et al. 2000,
Shukla et al. 2006, Rathore et al. 2011).
ICH guidelines (1999) also specifies the type of viruses that can be used in virus
clearance studies as shown in Table 1. Given the size of small parvovirus is very close to some
of the large mAb molecules, size selectivity is critical for virus filtration. Among all the wellstudied viruses, parvoviruses such as minute virus of mice (MVM) are normally chosen.
Table 1. Examples of Viruses that are being used in virus clearance studies
Virus

Genome

Envelope

Size (nm)

MuLV
BVDV
SV40
Polivirus sabin type I
Parvovirus

RNA
RNA
DNA
RNA
DNA

Yes
Yes
No
No
No

80-110
50-70
40-50
25-30
18-24

Resistance to
physical/chemical treatment
Low
Low
Very high
Very high
Very high

According to the definition by ICH guidelines (1999), viral clearance studies is to
validate 1) the effectiveness of a designated inactivation or a removal step as well as 2) the
overall virus reduction level during the entire process. A complete virus clearance study begins
with preparing challenge solution by spiking certain number of virus particles into the feed,
which in most cases being the mAb solution. Different fractions are then collected during the
virus inactivation/removal step. In the end, virus clearance performance will be assessed with
Process Analytical Techniques (PAT) such as qPCR, Plaque assay and TCID50 (Wang et al. 2005,
LaBarre et al. 2001). Because many virus filters are scalable (Huang et al., 2001), researchers are
able to challenge the small scale virus filters with much higher load of virus while obtaining
meaningful data that can be used to understand the large scale processes.
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1.3.

Virus Filtration

1.3.1. Virus Filtration Membranes
Virus Filtration (VF) membranes are normally used to separate proteins of 1-10 nm from viruses
of 18-110 nm (Van et al. 2007). Virus filtration should fall into the category of ultrafiltration (UF)
with membrane pore size of µm to nm in diameter. Most VF membranes are single-use and are
operated in normal flow (NFF or dead-end filtration) mode (Van et al. 2001). Because NFF VF
membranes are economically efficient and easy to scale up, they are more favored by the
biopharmaceutical manufacturers. Table 2 shows some examples of commercially available virus
filtration membranes.
Table 2. Commercially available virus filtration membranes
(Shukla et al. 2006; Bakhshayeshirad, 2011)
Vendor

Millipore

Pall

Asahi
Kasei

Sartorius

Brand

Target Virus

Operation Mode

Material

Viresolve® 70

Parvovirus

TFF

Hydrophilic
PVDF

>4 polivirus
>7 retrovirus

Viresolve® 180

Retrovirus

TFF

Parvovirus

NFF

Retrovirus

NFF

>3 polivirus
>6 retrovirus
>4 Phi-X174
bacteriophage
>6 retrovirus

Viresolve® Pro

Parvovirus

NFF

Hydrophilic
PVDF
Hydrophilic
PVDF
Hydrophilic
PES
Hydrophilic
PES

Ultipor® DV20

Parvovirus

NFF

Ultipor® DV50

Retrovirus

NFF

Pegasus® LV6

Retrovirus

NFF

Pegasus® SV4

Retrovirus

NFF

Planova® 15N

Parvovirus

TFF/NFF

Hydrophilic
CRC

Planova® 20N

Parvovirus

TFF/NFF

Hydrophilic
CRC

Planova® 35N

Retrovirus

TFF/NFF

Hydrophilic
CRC

Planova®
BioEX

Parvovirus

TFF/NFF

Virosart® CPV

Parvovirus

NFF

Viresolve®
NFP
Viresolve®
NFR

Hydrophilic
PVDF
Hydrophilic
PVDF
Hydrophilic
PVDF
Hydrophilic
PVDF

Modified
PVDF
Hydrophilic
PES

LRV

>4 parvovirus
>3 PP-7 bacteriophage
>6 PR-772 bacteriophage
>6 PR-772 bacteriophage
>6 retrovirus
>4 PP-7 bacteriophage
>6.2 parvovirus
>6.7 polivirus
>4.3 parvovirus
>5.4 encephalomyocardits
>5.9 BVD
>7.3 HIV
>4 parvovirus
>4 PP-7 bacteriophage,
>6 retrovirus
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The materials that VF membranes are made of are also very important. Different
materials have different membrane pore sizes and pore structures which will result in different
sieving properties for the VF membranes. Also, different VF membrane materials can have
different chemical and thermal stability which allows for different applications. The most
commonly used VF membranes are made from polyethersulfone (PES), polyvinylidene fluoride
(PVDF) and cuprammonium regenerated cellulose (CRC).
Most asymmetric membranes were operated with the side of small pore size facing the
feed. However, it has been shown that VF membranes perform better when the orientation is
reversed (Bakhshayeshi et al. 2008). This is because the support structure can function as a prefilter, remove aggregated proteins thus protects the skin side from fouling (Brown et al. 2010).
Membrane fouling is one of the biggest challenges in almost any types of filtration. In
virus filtration process, the major foulants are usually host-cell proteins, DNAs and protein
aggregates. Buffer condition plays an important role in filtration performance because the
conformation and properties of a mAb is pH and ionic strength dependent. Buffer also mediates
the electrostatic interactions among the mAb molecules, virus particles and virus filter (Ireland et
al, 2004). Previous studies also have indicated that high protein concentrations can result in high
possibility for the products to form aggregates and clog the membrane pores (Parkkinen et al.,
2005). Therefore, a number of lab scale filtration conditions will have to be tested in order to
find the optimal operation conditions that are suitable for the large scale processing.
In this thesis research, polyethersulfone (PES) membranes with different molecular
weight cut-off (MWCO) were challenged with two different protein solutions (Bovine Serum
Albumin, BSA and Lysozyme) at various concentrations. Flux and virus titer from each fraction
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collected were measured to evaluate the effects of pH, membrane pore size and challenging
protein solutions on virus filtration performance.
1.3.2. Virus
Being the smallest microorganisms on the earth, a virus consists of a genetic material (DNA or
RNA, can be either single stranded or double stranded) encapsulated by a protein capsid, and
sometimes surrounded by an additional spikey lipid coat called an envelope. Virus can only
replicate in the living cells and can only attack certain types of host organisms (van et al., 2000).
For example, human immunodeficiency virus (HIV) only infects mammalian cells while
bacteriophage only infects bacteria only. As shown in Table 1, FDA recommends different size
viruses as model viruses for clearance studies. Because mAbs are typically produced in Chinese
Hamster Ovary (CHO) cells (Trill et al. 1995), which are the targets of certain types of
mammalian viruses including minute virus of mice (MVM) and murine leukemia virus (MuLV)
(Mascarenhas et al. 2016, Strauss et al. 2009). Biopharmaceutical manufacturers tend to use
MuLV (a model retrovirus, enveloped, 80-110 nm in diameter) representing large viruses and
MVM (a parvovirus, non-enveloped, Φ=18-24 nm) representing smallest viruses for clearance
studies (Han et al. 2005, Gruvegard et al., 2009).
While using closely related mammalian virus for virus clearance studies is intuitively
appropriate, these viruses typically require a long period of time for cell culture and virus titer
analysis, and require higher biosafety levels. Bacteriophages, on the other hand, have some
advantages over mammalian viruses for the virus clearance studies. For example, bacteriophage
requires a lower biosafety level and is generally considered less of a biological threat to the
laboratory personnel.
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In our studies, a non-enveloped 25-27 nm single-stranded DNA bacteriophage Phi-X174
(Chrysikopoulos et al., 2011) and an 82 nm double-stranded DNA bacteriophage PR-772 (Lute
et al., 2004) were used as the surrogates for the virus filtration experiments. The icosahedral
bacteriophage Phi-X174 has a spherical shape (Chrysikopoulos et al., 2011, Sun et al., 2014).
The burst of a single host cell is approximately 16 min after infection yielding 150 to 200
infectious virions (Sinsheimer et al., 1968). PR-772 is a double strand DNA bacteriophage with
a lipid membrane beneath its icosahedral shell (Lute et al., 2004), Parenteral Drug Association
has developed a standard large-virus filter based on the retention of bacteriophage PR-772
(Aranha-Creado et al., 1997).
2.

Material and Methods

2.1.

Materials

Bovine Serum Albumin (> 99%) were purchased from Sigma Aldrich (St Louis, MO). Lysozyme
(egg white, > 95%) was purchased from OmniPur (Gibbstown, NJ). Sodium chloride (ACS
grade) was purchased from Macron Fine Chemicals (Center Valley, PA). 2XYT medium broth
were purchased from AMRESCO. Host cells and viruses were purchased from ATCC (Manassas,
Virginia). The two bacterial hosts were Escherichia coli (Migula) Castellani and Chalmers
(ATCC #13706) and Escherichia coli strain K12 J53-1 (ATCC #BAA-769). Upon arrival,
viruses were further propagated via their corresponding host cells: Escherichia coli
bacteriophage Phi-X174 (ATCC 13706-B1) and Escherichia coli bacteriophage PR-772 (ATCC
BAA-769-B1). Polyethersulfone (PES) membranes of three pore sizes (30 kDa, 100 kDa, 300
kDa) were obtained from EMD Millipore Corporation.
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2.2.

Virus Stock Preparation

Host cells were grown in a flask containing 2XYT medium broth under aerobic condition with a
preset shaking speed of 200 rpm at 37oC following the ATCC cell culture protocols. When the
bacterium culture reached an absorbance value of 0.600 at the wavelength of 600 nm, the cell
culture medium was then spiked with 1% (v/v) of PFU=108 virus stock. The virus culture was
then under constant shaking for 24 hours. Host cells were then lysed by three freeze–thaw cycles.
Lysate was centrifuged at 9,500 g / 8,874 rpm under room temperature using Beckman Coulter
Avant J-25 High Performance Centrifuge and JA-25.50 fixed angle rotor for 30 minutes to
isolate free virus particles from host cells lysate. The supernatant containing high titer of viruses
was collected and further purified by filtering through a 0.2 μm Thermo Fisher Disposable
Vacuum Filter System. When not in use, the purified virus stocks were either kept at 4oC for
short term storage or frozen at -80oC for long-term storage.
2.3.

Flux Measurement

The filtration experimental design was derived based on the method described by
Wickramasinghe et al. (2010). Filtration experiments were performed by three PES membranes
with MWCO of 30 kDa, 100 kDa and 300 kDa respectively. These are asymmetric membranes
with a barrier layer and a porous support structure. All membranes were initially filtered with 20
mL DI water and 20 mL broth before filtration of any virus feed solutions. All filtration
experiments were performed in a laminar flow cabinet with an 8050 Amicon stirred cell. The
8050 Amicon stirred cell has a reported filter diameter of 44.5 mm and was set up in the normal
flow filtration (NFF) mode at a constant pressure of 2 psi.
A DI water flush and a broth media flush were performed for each membrane before the
filtration of the feed solutions. A total volume of 100 mL of feed solution was used for each
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filtration experiment. A total of 10 fractions about 10 mL each were taken from the permeate.
Fraction weight was calculated by subtracting the tube weight from the measured weight using
mass balance. Fraction density was calculated by measuring the weight difference before and
after taken 1 mL fraction out of fraction tube. Fraction volume was calculated by dividing
fraction weight by fraction density. Flux data were then plotted based on the volume from each
fraction and filtration time.
2.4.

Titer Analysis

Each fraction was analyzed using Clokie and Kropinski’s Bacteriophage plaque counting method
(Kropinski et al., 2008) to determine the virus titer. Upper agar media solution (31g/L 2XYT
medium broth and 7g/L agar) was prepared and incubated in a warm water bath at 50oC for 15
min. Base agar media solution (31g/L 2XYT medium broth and 15g/L agar) was poured into
base cell culture plates and sit in the laminar flow cabinet for 20 min to allow solidification. Host
cells were grown till absorbance reached 0.600 at the wavelength of 600 nm. A total of 190 μL
aliquots of the host cells along with their cell culture media were spiked with 10 μL of either an
original fraction or a sequential 10x diluted fraction. For each filtration, sample plates were used
to determine appropriate dilution fold. The 200 μL solution containing logarithmic growth phase
host cells and virus filtration fraction (seed solution) were briefly vortexed and allowed to sit at
37oC for 15 min for sufficient pre-infection. A total of 200 μL seed solution was then quickly
mixed with pre-warmed 3 mL of upper agar media solution and was poured onto the top of a
base plate containing 15 mL of pre-warmed and solidified base agar and allowed solidification in
the laminar flow cabinet. When solidified, the double agar plates were transferred into a 37oC
incubator overnight to allow plaque forming. Plaque counting was performed the next day and
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were done on each plate. Each fraction was repeated three times. Plaque Forming Units (PFU)
and Log Removal of Virus (LRV) for each fraction are calculated using the formulas below:
ℎ

=

×
! =

3.

"#

Results and Analysis

A series of filtration experiments with different feed solutions were performed to explore their
effects on flux and virus rejection with different pore size membranes.
3.1.

Pore Size Effect

PES membranes of three different pore sizes (PES 30 kDa, PES 100 kDa and PES 300 kDa)
were tested to investigate the effect of pore size on flux performance and bacteriophage
clearance during the filtration challenge. The 8050 Amicon stirred cell was used in the dead-end
mode for the filtration experiments. Harvested high titer bacteriophage stock solutions were used
as the feed solution in this study. The feed solution was loaded into the Amicon stirred cell
immediately after 20 min DI water flush and broth media flush respectively. A total of 10
fractions were collected from the permeate for flux measurement and titer analysis.
Figures 1 and 2 show the flux and log reduction value (LRV) of Phi-X174 respectively
for the 10 fractions collected. As is shown in Figure 1, PES 300 kDa membrane exhibits highest
initial flux at 48.5 LMH whereas both 100 kDa and 30 kDa membranes show a much reduced
flux at around 12 LMH only. However, significant flux decay was observed for 300 kDa
membrane during the subsequent measurements reaching 14 LMH during the last fraction. On
the other hand, the other two narrower pore size membranes did not demonstrate much flux
decay during the entire filtration period. The high flux decay for the 300 kDa membrane could
11

be attributed to severer membrane fouling resulting from the plugging of the membrane pores.
As can be seen from Figure 2, the LRV for the 300 kDa membrane is below 1 during the first 80
mL of the filtration. Viruses can easily go through the membrane plugging the membrane pores.
As more pores are being plugged, the rejection of the virus increases with LRV reaching 1.3 at
the end of the filtration. For the 100 kDa and 30 kDa membranes, membrane pores are much
smaller than the Phi-X174 virus particle leading to the high rejection of the virus at the start of
the filtration experiments. The LRV for both membranes are at around 3.5 indicating that over 99%
of the virus particles are rejected. Moreover, starting from the third fraction, the LRV increases
steadily to 4 and above indicating that plugging of the pores by viruses and cell debris leading to
an enhanced rejection of the virus particles and slightly reduced fluxes. The cake layer formation
on the membrane surface may also contributed to the improved rejection and somewhat reduced
fluxes. After 8 fractions, the LRV further increases reaching 5 during the next several fractions.
The flux decay for the 100 kDa and 30 kDa membranes is less than 30% during the entire
filtration period indicating that cake layer formation on membrane surface and pore plugging do
not affect the flux as much as the rejection of the virus particles.
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Figure 1. Flux measurement during Phi-X174 virus filtration with PES 30, 100 and 300 kDa
membranes.

13

7.0

Log Reduction Value (LRV)

6.0
5.0
4.0

PES 300kDa
PES 100kDa

3.0

PES 30kDa

2.0
1.0
0.0
0

20

40

60
80
100
Filtered Volume, mL

120

140

160

Figure 2. Titer analysis for Phi-X174 filtration for each fraction collected with PES 30, 100 and
300 kDa membranes.
3.2.

Protein Spiking Effect

A total of 4 feed solutions were prepared by dissolving protein powders in harvested high titer
virus stock solutions to reach final concentrations of 0.5% [w/v] BSA and 1% [w/v] BSA, 0.5%
[w/v] lysozyme and 1% [w/v] lysozyme respectively. After dissolving BSA and lysozyme
powder in the virus stocks, the solutions were stirred for 30 minutes and filtered through a 0.2
μm Thermo Disposable Vacuum Filter System. The pH of the feed solutions was measured to be
6.5. The feed solution was loaded into the Amicon stirred cell immediately after a DI water flush
14

and a broth media flush. Nearly 10 fractions were collected from the permeate for flux
calculation and titer analysis. The number of fractions collected depends on the flux towards the
end of filtration.
With the presence of proteins in the process stream, the flux decreases significantly
(Figure 3, 5 7). This effect is more evident when using a smaller MWCO membrane for virus
filtration (Figure 4). BSA appears to be more likely to cause membrane fouling when spiked into
the feed solutions compared to lysozyme and the flux decline was more significant as shown in
Figures 4 and 6. The titer analysis results indicate that the presence of proteins in the feed
streams can lead to a higher LRV as plotted in Figures 5 and 7. The concentration of the spiked
protein also plays an important role in the dramatic flux decay during virus filtration. In both
scenarios, flux decay was much faster when the feed stream was spiked with higher
concentration protein. However, titer analysis indicate that protein concentration does not have a
significant impact on the LRV as seen from Figures 5 and 7. The presence of lysozyme in the
feed stream showed a higher LRV and lower flux than those in the presence of BSA. Zeta
potential measurement (Salinas-Rodriguez et al, 2015) show that PES membrane is negatively
charged at close to neutral pH. Lysozyme and BSA have pI values of 11.35 and 4.7 respectively
leading to the positively charged state for the former and negatively charged state for the latter at
pH= 6.5. The positively charged lysozyme will likely form a cake layer on the negatively
charged PES membrane surface. This leads to a strong initial reduction of the flux in the
presence of lysozyme. In the case of feed solutions spiked with BSA protein, the electrostatic
repulsion leads to a low probability of a cake layer formation. The 66 kDa BSA protein is more
likely to cause pore plugging of the PES membrane compared to much smaller lysozyme. As a
result, the initial fluxes are lower for feed solutions spiked with lysozyme but a smaller flux
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decay over time. On the other hand, the initial fluxes are higher for the feed solutions spiked with
BSA but a higher flux decay over time as shown in Figure 4 with 100 kDa PES membrane.
Consequently, the initial LRV of ~5 is higher in the presence of lysozyme compared to that of
BSA at ~4. As more pores are plugged by BSA, the LRV increases steadily for the subsequent
fractions collected reaching a steady value of 5.8 similar to the LRV with lysozyme. For the feed
solution without any spiked protein, the flux decays rapidly at the beginning but a steady state is
established quickly. The LRV is significantly lower without spiked protein, but increases
steadily reaching 5.6 at the final fraction collected due to membrane fouling. For PES 300 kDa as
shown in Figures 4 and 6, similar trends are found but the overall LRV is much smaller.
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Figure 3. Flux measurement under different protein spiking conditions with PES 100 and 300
kDa membranes.
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Figure 4. Flux measurement during Phi-X174 filtration using PES 100 kDa membrane in the
absence and presence of lysozyme and BSA proteins at different concentrations.
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Figure 5. Titer analysis on each fraction collected from Phi-X174 filtration using PES 100 kDa
membrane in the absence and presence of lysozyme and BSA proteins at different concentrations.
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Figure 6. Flux measurement during Phi-X174 virus filtration using PES 300 kDa membrane in
the absence and presence of lysozyme and BSA proteins at different concentrations.
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Figure 7. Titer analysis on each fraction collected from Phi-X174 filtration using PES 300 kDa
membrane in the absence and presence of lysozyme and BSA proteins at different concentrations.
3.3.

pH Effect

Challenge solutions of 5 different pH conditions ranging from 5.50 to 6.94 were tested against
PES 100 kDa membrane to investigate the effects of pH on flux performance and bacteriophage
clearance. The solutions were prepared by dissolving BSA protein powders in harvested high
titer virus stock solutions to reach final concentrations of 1% [w/v]. The solutions were then
stirred for 30 minutes and filtered through a 0.2 μm filter. pH adjustment was made right after
the protein spiking but prior to the sterile filtration. The feed solution was loaded into the
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Amicon stirred cell immediately after DI water flush and a broth media flush. A total of 10
fractions were collected from the permeate for flux calculation and titer analysis.
As shown in the Figure 8, there is no significant influence of pH on flux in the pH range
tested except a higher flux was observed for pH = 6.97. Moreover, there is no significant
difference in bacteriophage clearance under different filtration pH conditions as shown in Figure
9. The results indicate that at the pH values investigated, the virus, protein and membrane are all
negatively charged. The effects of pH on flux and LRV are similar. However, at pH close to 7,
the electrostatic repulsion is even stronger, thus a higher initial flux was found. As more proteins
are deposited on the membranes due to fouling, flux decay were observed for all the pH
conditions, but more pronounced at pH close to 7.
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Figure 8. Flux measurement during Phi-X174 filtration using PES 100 kDa membrane spiked
with 1% w/v BSA under multiple solution pH conditions.
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Figure 9. Titer analysis on each fraction collected from Phi-X174 filtration using PES 100 kDa
membrane and spiked with 1% w/v BSA under various pH conditions.
3.4.

Phage spiking Effect

Harvested high titer PR-772 and Phi-X174 phage stock solutions were tested against PES 300
kDa membrane to investigate phage spiking effect on flux performance and bacteriophage
clearance. The feed solution was loaded into the Amicon stirred cell immediately after DI water
flush and broth media flush. Nearly 10 fractions were collected from the permeate for flux
calculation and titer analysis.
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As shown in Figure 10, PR-772 filtration has a much lower flux compared to that of PhiX174. PES 300 kDa membrane can reject many more PR-772 particles than Phi-X174 virus
under the same operating condition as shown in Figure 11. This phenomenon can be explained
by the fact that PR-772 has a diameter of 82 nm (Lute et al., 2004) which is larger than the
MWCO of PES 300 kDa membrane and much larger than the 26 nm Phi-X174.
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Figure 10. Flux measurement during Phi-X174 filtration and PR-772 filtration using PES 300
kDa membrane.
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Figure 11. Titer analysis on each fraction collected from Phi-X174 filtration and PR-772
filtration using PES 300 kDa membrane.
4.

Discussion

Although virus filtration is typically thought to be a size exclusion-based process, previous
studies have shown that virus removal is a function of solution pH, ionic strength of the filtration
buffer, isoelectric point of the testing proteins, isoelectric point of virus and the zeta potential of
testing VF filter (Schaldach et al., 2006, Bakhshayeshi et al., 2008). These abovementioned
effects result in virus adsorption, virus aggregation and protein-virus complexes formation etc.
(Zerda et al., 1985)
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The results of protein spiking effect as shown in Figures 3 demonstrate that flux
decreases as protein concentration increases in the feed streams. The LRV is more affected by
the protein type rather than by the concentration as is shown in Figure 5 and Figure 7. Lysozyme
can lead to a higher LRV and a lower filtration flux than BSA at same feed concentration as is
shown in Figure 4-7.
The size of BSA ranges between 9 to 25nm (Reichert et al. 2005) which is close to the
MWCO of the PES 100 kDa membrane as well as the size of Phi-X174 bacteriophage. The size
of lysozyme is approximately 1.9 nm (Ecker et al., 2015). However, these two proteins are
oppositely charged at the filtration pH conditions. Therefore, when spiked with BSA, the
membrane will most likely undergo a cake filtration process with partial pore blocking caused by
electrostatic repulsion between BSA and PES membrane (Stump et al., 2007). However, when
spiked with lysozyme, the PES membrane will most likely undergo a cake filtration process with
standard pore blocking, caused by electrostatic attraction between lysozyme and PES membrane
(Stump et al., 2007).
5.

Future Directions

Future work will be focus on assessing the virus clearance and flux performance using a wider
range of filtration conditions to enhance the process understanding and unveil the filtration
mechanism. Various titer analysis methods will be used to measure the titer of both intact virus
particles as well as partial damaged virus particles. Virus of different types including PPV and
mammalian viruses will also be used as validation model in the filtration studies. Also given that
the virus clearance and flux performance can be both product specific and process specific. We
will be also considering to use proteins of different types and a broader spiking concentration
ranges in the future virus filtration studies.
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